Search results
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Motley Fool via Yahoo Finance· 1 day agoFood and Drug Administration (FDA). AbCellera was valued above $15 billion following its initial public offering in late 2020. Unfortunately, the FDA...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days agoLife360 (NASDAQ: LIF), a San Francisco-based tracking app company, was featured in a recent Fox Business article. The article highlighted the company’s debut as a
Rapport Therapeutics director buys $9.5 million in company stock By Investing.com
Investing.com· 4 days agoDirector of Rapport Therapeutics, Inc. (NASDAQ:RAPP), James Healy, has recently made a substantial...
J&J-backed Rapport Therapeutics valued at $636.8 million after shares rise 6% in debut
WHTC 1450 Holland· 7 days ago(Reuters) - Shares of Rapport Therapeutics, backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 ...
Should You Buy Arm Holdings Right Now or Wait for a Pullback?
Motley Fool via Yahoo Finance· 5 days agoDeciding when to purchase a stock is perhaps an investor's most challenging decision. This is...
This Needham biotech's stock has gone up 700% in 3 months - Boston Business Journal
The Business Journals· 4 days agoCandel Therapeutics Inc. has been working on its comeback story. After its initial public offering...
Newsmax Considers IPO With Private Placement of Up to $225 Million
The Wall Street Journal· 4 days agoBoca Raton, Fla.-based Newsmax said Monday in an investor presentation posted to its website that it...
Down 27% From Its 52-Week High, Is Now the Time to Buy Fortinet Stock?
The Motley Fool via AOL· 5 days agoFor investors who are confident in the company's long-term potential, the recent stock price...
J&J-backed Rapport Therapeutics valued at $636.8 million in lukewarm debut
Reuters via Yahoo News· 7 days agoU.S. IPOs are seeing a rebound this year, after an almost two-year dry spell when high interest rates, market volatility and geopolitical turmoil marred investors' risk appetite. Among other ...
Down 27% From Its 52-Week High, Is Now the Time to Buy Fortinet Stock?
Motley Fool via Yahoo Finance· 5 days agoFor investors who are confident in the company's long-term potential, the recent stock price...